Clinical Study
Management of Bladder Cancer following Solid Organ Transplantation
Table 1
Characteristics of patients with nonmuscle-invasive TCC of the bladder.
| Patient number | 1, 2 | 3 | 4 | 5 | 6 | 7 |
| Age at transplant | 66 | 77 | 82 | 66 | 63 | 45 | Type of transplant | Liver | Renal | Renal | Renal | Liver | Renal | Age at diagnosis | 66 | 79 | 83 | 72 | 65 | 47 | Immunosuppression | FK, MMF, Pred | FK, Pred | FK | FK, MMF | FK, Pred | FK, Pred | Clinical stage | T1NxMx | T1NxMx | TisNxMx | TisNxMx | TisNxMx | T1N0Mx | Histology | TCC | TCC | CIS | CIS | CIS | TCC | Grade | Low | Low | High | High | High | High | Treatment | TURBT | TURBT | TURBT | TURBT | TURBT | Cystectomy, ureteroureterostomy | Adjuvant therapy | None | BCG | BCG | BCG | BCG | Mitomycin C | Followup (months) | 28, 24 | 40 | 36 | 84 | 42 | 98 | Recurrence | None | Local | Local | None | Local | None |
|
|
FK: tacrolimus; MMF: mycophenolate mofetil; Pred: prednisone; CIS: carcinoma in site; TURBT: transurethral resection bladder tumor; BCG: bacille-Calmette Guerin.
|